[go: up one dir, main page]

US3591697A - 1,4-dihydro - 1 - substituted-6,7-methylenedioxy-4-oxo -3-quinoline carboxylic acid antibacterial agents - Google Patents

1,4-dihydro - 1 - substituted-6,7-methylenedioxy-4-oxo -3-quinoline carboxylic acid antibacterial agents Download PDF

Info

Publication number
US3591697A
US3591697A US47893A US3591697DA US3591697A US 3591697 A US3591697 A US 3591697A US 47893 A US47893 A US 47893A US 3591697D A US3591697D A US 3591697DA US 3591697 A US3591697 A US 3591697A
Authority
US
United States
Prior art keywords
oxo
dihydro
methylenedioxy
percent
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US47893A
Inventor
Daniel Kaminsky
Robert I Meltzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Pharmaceutical Co filed Critical Warner Lambert Pharmaceutical Co
Application granted granted Critical
Publication of US3591697A publication Critical patent/US3591697A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Definitions

  • R represents alkyl, substituted lower alkyl, cycloalkyl, alkenyl and aralkyl;
  • R represents O-alkyl, O-mono or dialkylaminoalkyl, O-cycloalkyl, NH-alkyl, NH-aryl,
  • R represents lower alkyl, substituted lower alkyl, preferably hydroxy lower alkyl, carboxy lower alkyl, lower alkenyl and cycloalkyl;
  • R represents O-alkyl, O-mono or dialkylaminoalkyl, NH-lower alkyl, NH-aralkyl, NH-aryl,
  • R is lower alkyl or aralkyl and R is lower alkyl or R and R taken together with the nitrogen atom may constitute a cyclic moiety such as morpholino, piperidino, or piperazino, etc., and R may also be any readily hydrolyzable group, such as a thioester, nitrile, or the like.
  • R, R R and R alkyl is meant to include those alkyl groups containing 1 to 12 carbon atoms in a straight or branch chain such as methyl, ethyl, propyl, isopropyl, and the like; cycloalkyl is meant to include from 3 to 8 carbon atoms, such as cyclopropyl,
  • aralkyl is meant to include both monohomocyclic ring systems, such as benzy as well as heteroaromatic ring systems such as pyridyl, furyl and the like.
  • the definitions R, R R and R as used hereinafter are to be considered to have the meanings defined above.
  • compositions of this invention exhibit potent antibacterial activity particularly against gram negative bacteria, such as the Escherichia group, for example, E. coli and the Proteus group, for example, P. vztlgaris. Accordingly, they are useful as anti-bacterial agents in the treatment of mammals, such as dogs, guinea pigs, cats, monkeys, and the like, which-are infected with bacteria susceptible to these agents.
  • mammals such as dogs, guinea pigs, cats, monkeys, and the like, which-are infected with bacteria susceptible to these agents.
  • an inert pharmaceutical carrier such as lactose, starch, dicalcium phosphates, syrup, and the like, to yield various dosage forms such as tablets, suspensions and the like, with the active ingredient being present in amounts of from about to 500 mg. per dosage unit.
  • sterile vehicles such as sterile water, or sterile isotonic saline to form dosage forms suitable for parenteral administration.
  • These dosage forms may be compounded according to standard pharmaceutical art. Generally, a dosage regimen of about 100 mg. to 1500 mg., preferably about 250 mg., 3 or 4 times daily, orally or by injection are recommended to treat bacterial infections caused by these gram negative bacteria.
  • a surprising property of these compositions resides in the discovery that they are more slowly metabolized in the mammalian body and consequently, they are longer acting when compared with other quinoline compounds such as those disclosed in US. Pat. No. 3,287,458. Because of this prolonged activity, the dosage that is necessary to be administered to a host may be considerably reduced.
  • the compounds of this invention may also be administered in admixture with animal food stuffs, for example, they may be mixed from 1 to 25% by weight with food stuffs such as corn meal, water, and the like.
  • compositions may comprise from about 1 to 20% by weight of the selected active ingredient and such standard pharmaceutical, diluents which are commonly used in the manufacture of topical compositions, such as talc, Vaseline, or other hydrophobic or hydrophilic ointment bases, and the like. These compositions are applied to infected sites.
  • compositions of this invention may also include other known anti-bacterials, such as the tetracyclines, the nitro-furans, the sulfa drugs, and the like to enhance their anti-bacterial spectrum.
  • other known anti-bacterials such as the tetracyclines, the nitro-furans, the sulfa drugs, and the like to enhance their anti-bacterial spectrum.
  • compositions containing as active ingredients an anti-bacterially effective amount of a compound according to Structure 1 above wherein R is lower alkyl, hydroxy-lower alkyl, carboxy-lower alkyl, lower alkenyl and cycloalkyl, in which cycloalkyl contains from 3 to 8 carbon atoms; R is 0- alkyl, preferably O-lower alkyl, O-mono alkyl or diloweralkyl or O-cycloalkyl in which cycloalkyl contains from 3 to 8 cabon atoms and NHOH, NHCOOR in which R is lower alkyl in an inert pharmaceutical carrier.
  • R is lower alkyl, hydroxy-lower alkyl, carboxy-lower alkyl, lower alkenyl and cycloalkyl, in which cycloalkyl contains from 3 to 8 carbon atoms
  • R is 0- alkyl, preferably O-lower alkyl, O-mono alkyl or diloweralky
  • the active ingredients of this invention are prepared by four different methods.
  • Method A a compound of the formula:
  • R is O-lowcr alkyl, O-dialkylaminoalkyl, O-cycloalkyl, and O-lower alkenyl.
  • EXAMPLE 10 The acid chloride obtained by treatment of 1,4-dihydro- 1 methyl-6,7-methylenedioxy 4 oxo-3-quinolinecarboxylic acid with thionyl chloride as in Method A, Example 1, was treated, without isolation, with ethanol to yield ethyl 1,4-dihydro-1-methyl 6,7 methylenedioxy-4- oxo-3-quinolinecarboxylate, M.P. 202-203.
  • EXAMPLE 11 The acid chloride obtained by treatment of 1,4-dihydro- 6,7 methylenedioxy-4-oxo l propyl 3 quinoline carboxylic acid with thionyl chloride, as in Method A, Example 1, was treated, without isolation, with ethanol to yield ethyl 1,4-dihydro 6,7 methylenedioxy 4 oxo-lpropyl-3-quinolinecarboxylate, M.P. 147l49.
  • EXAMPLE 12 The acid chloride obtained by treatment of 1-butyl-1,4- dihydro-6,7-methy1enedioxy 4 oxo 3 quinoline carboxylic acid with thionyl chloride, as in Method A, Example 1, was treated, without isolation, with ethanol to yield ethyl 1-butyl-l,4-dihydro 6,7 methylenedioxy-4- oxo-3-quinoline carboxylate, M.P. 117-119".
  • R is lower alkyl, hydroxy-lower alkyl, carboxylower alkyl, lower alkenyl, or cycloalkyl, in which cycloalkyl contains from 3 to 8 carbon atoms;
  • R is NHOH, NHCOO'R in which R is lower alkyl in an inert pharmaceutical carrier.
  • a method for treating gram negative bacterial infections in a mammal which comprises administration to said mammal an eifective anti-bacterial amount of a composition according to claim 1.
  • composition contains as active ingredient the compound having the following structural formula:
  • composition of claim 1 is administered at a dose of about 250 mg. several times daily.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract


-N(-R2)-R3, NH-(CH2)P-N(-R2)-R3

WHEREIN R REPRESENTS ALKYL, SUBSTITUTED LOWER ALKYL, CYCLOALKYL, ALKENYL AND ARALKYL; R1 REPRESENTS 0-ALKYL, O-MONO OR DIALKYLAMINOALKYL, O-CYCLOALKYL, NH-ALKYL, NH-ARYL,

5-R,7-(R1-OC-)-1,3-DIOXOLO(4,5-G)QUINOLIN-8(5H)-ONE

THE PRESENT INVENTION RELATES TO COMPOSITIONS OF MASTER CONTAINING QUINOLINES OF THE FORMULA:
NHCOOR2, NHOR, OR ANY READILY HYDROLYZABLE GROUP. THESE COMPOUNDS ARE USEFUL AS ANTI-MICROBIAL AGENTS.

Description

United States Patent @ffice Ser. No. 47,893
Int. Cl. A61k 27/00 Us. Cl. 424-258 4 Claims ABSTRACT OF THE DISCLOSURE The present invention relates to compositions of matter containing quinolines of the formula:
wherein R represents alkyl, substituted lower alkyl, cycloalkyl, alkenyl and aralkyl; R represents O-alkyl, O-mono or dialkylaminoalkyl, O-cycloalkyl, NH-alkyl, NH-aryl,
NHCOOR NHOR, or any readily hydrolyzable group. These compounds are useful as anti-microbial agents.
This application is a continuation-in-part application of our copending application, U.S. Ser. No. 639,304, filed May 18, 1967, now US. Pat. No. 524,858. -The present invention relates to anti-bacterial compositions containing as active ingredients, l,4 dihydro-1-R- 6,7-methylene-dioxy-4oxo-3-quino1ine carboxylic acid derivatives of the formula:
d-R, OH: I
wherein R represents lower alkyl, substituted lower alkyl, preferably hydroxy lower alkyl, carboxy lower alkyl, lower alkenyl and cycloalkyl; R represents O-alkyl, O-mono or dialkylaminoalkyl, NH-lower alkyl, NH-aralkyl, NH-aryl,
/Rz /R, N NH-(OHfln-N Ra Ra where n is 1 to 4, --NHCOOR in which R is lower alkyl or aralkyl and R is lower alkyl or R and R taken together with the nitrogen atom may constitute a cyclic moiety such as morpholino, piperidino, or piperazino, etc., and R may also be any readily hydrolyzable group, such as a thioester, nitrile, or the like.
In the above definitions of R, R R and R alkyl is meant to include those alkyl groups containing 1 to 12 carbon atoms in a straight or branch chain such as methyl, ethyl, propyl, isopropyl, and the like; cycloalkyl is meant to include from 3 to 8 carbon atoms, such as cyclopropyl,
3,591,697 Patented July 6, 1971 cyclobutyl, cyclohexyl and the like; aralkyl is meant to include both monohomocyclic ring systems, such as benzy as well as heteroaromatic ring systems such as pyridyl, furyl and the like. The definitions R, R R and R as used hereinafter are to be considered to have the meanings defined above.
The compositions of this invention exhibit potent antibacterial activity particularly against gram negative bacteria, such as the Escherichia group, for example, E. coli and the Proteus group, for example, P. vztlgaris. Accordingly, they are useful as anti-bacterial agents in the treatment of mammals, such as dogs, guinea pigs, cats, monkeys, and the like, which-are infected with bacteria susceptible to these agents. In order to use these compounds, they are combined with an inert pharmaceutical carrier such as lactose, starch, dicalcium phosphates, syrup, and the like, to yield various dosage forms such as tablets, suspensions and the like, with the active ingredient being present in amounts of from about to 500 mg. per dosage unit. They may also be combined with sterile vehicles, such as sterile water, or sterile isotonic saline to form dosage forms suitable for parenteral administration. These dosage forms may be compounded according to standard pharmaceutical art. Generally, a dosage regimen of about 100 mg. to 1500 mg., preferably about 250 mg., 3 or 4 times daily, orally or by injection are recommended to treat bacterial infections caused by these gram negative bacteria. A surprising property of these compositions resides in the discovery that they are more slowly metabolized in the mammalian body and consequently, they are longer acting when compared with other quinoline compounds such as those disclosed in US. Pat. No. 3,287,458. Because of this prolonged activity, the dosage that is necessary to be administered to a host may be considerably reduced.
The compounds of this invention may also be administered in admixture with animal food stuffs, for example, they may be mixed from 1 to 25% by weight with food stuffs such as corn meal, water, and the like.
The compounds of this invention may also be used in a form suitable for topical application. Such compositions may comprise from about 1 to 20% by weight of the selected active ingredient and such standard pharmaceutical, diluents which are commonly used in the manufacture of topical compositions, such as talc, Vaseline, or other hydrophobic or hydrophilic ointment bases, and the like. These compositions are applied to infected sites.
The compositions of this invention may also include other known anti-bacterials, such as the tetracyclines, the nitro-furans, the sulfa drugs, and the like to enhance their anti-bacterial spectrum.
Among the preferred compositions are those compositions containing as active ingredients an anti-bacterially effective amount of a compound according to Structure 1 above wherein R is lower alkyl, hydroxy-lower alkyl, carboxy-lower alkyl, lower alkenyl and cycloalkyl, in which cycloalkyl contains from 3 to 8 carbon atoms; R is 0- alkyl, preferably O-lower alkyl, O-mono alkyl or diloweralkyl or O-cycloalkyl in which cycloalkyl contains from 3 to 8 cabon atoms and NHOH, NHCOOR in which R is lower alkyl in an inert pharmaceutical carrier.
The active ingredients of this invention are prepared by four different methods. In the first method (referred to as Method A in the examples below) a compound of the formula:
is treated with an alcohol, for example, methanol, diethylaminoethanol, cyclohexanol, and the like, to yield these compounds wherein R is O-lowcr alkyl, O-dialkylaminoalkyl, O-cycloalkyl, and O-lower alkenyl.
In the second method (referred to as Method B in the examples) employing analogous reaction conditions, compound II above is treated with a suitable amine to yield compounds wherein R is NH-alkyl, NH-aryl, NH-aralkyl,
In the third method (referred to as Method C in the examples) compound II is treated with hydroxylamine or substituted hydroxylamines to yield compounds wherein R is NHOH or NHOR.
In the fourth method (referred to as Method D in the examples) compound II is treated with a carbamate ester (such as ethyl carbamate) to yield compounds wherein R is NHCOOR. Starting compound II is obtained by treating quinolines of the formula:
with thionyl chloride, oxalyl chloride or other agents generally used to convert acids to acid chlorides. Compound III is described and disclosed in U.S. Pat. No. 3,287,458.
The following examples are included in order further to illustrate the invention.
METHOD A.EXAMPLE 1 l-Ethyl-1,4-dihydro-4-oxo-6,7-methylenedioxyq'uinoline-3-carbonyl chloride (III) 4-oxo-6,7-methylenedioxy-quinoline-3-carbonyl chloride, M.P. 245 (dec.).
Analysis.Calcd. for C H ClNO (percent): C,
55.83; H, 3.60;. N, 5.01; Cl, 12.68. Found (percent): C, 56.03;H, 3.87; N, 4.94; Cl, 12.87.
EXAMPLE 2 Cyclohexyl 1-ethyl-1,4-dihydro-4-oxo-6,7-methylenedioxy-quinoline-3-carboxylate A mixture of 14 g. (0.05 mole) of l-ethyl-l,4-dihydro- 4-oxo-6,7-methylenedioxy-quinoline 3 carbonyl chloride, 6 g. (0.06 mole) of freshly distilled cyclohexanol and 30 g. of pyridine was heated for 2 hrs. on a steam bath. The volatiles were removed in vacuo and the residue was triturated several times with Water and filtered. The crude product was recrystallized from 3:1 CCl :Skellysolve B yielding 15.4 g. (90%) of cyclohexyl l-ethyl-1,4- dihydro-6,7-methylenedioxy 4 oxo 3 quinoline-carboxylate, M.P. 204206.
Analysis.-Calcd. for C H NO (percent): C, 66.46; H, 6.16; N, 4.08. Found (percent): C, 66.46; H, 6.24; N, 3.91.
EXAMPLE 3 Following the procedure of Example 2 and employing analogous reaction conditions, but using ethanol, instead of cyclohexanol, there was obtained ethyl 1-ethyl-l,4-di- 4 hydro-6,7-methylenedioxy 4 oxo 3 quinolinecarboxylate, M.P. 177178.
AnaIysis.-Calcd. for C H NO (percent): C, 62.28; H, 5.23; N, 4.48. Found (percent): C, 61.99; H, 5.07; N, 4.71.
EXAMPLE 4 Following the procedure of Example 2 and employing analogous reaction conditions, but using n-propanol instead of cyclohexanol, there was obtained propyl l-ethyl- 1,4-dihydro-6,7-methylenedioxy 4 oxo 3 quinolinecarboxylate, M.P. 159-l60.
Analysis.Calcd. for C H NO (percent): C, 63.36; H, 5.56; N, 4.62. Found (percent): C, 63.13; H, 5.72; N, 4.74.
EXAMPLE 5 Following the procedure of Example 2 and employing analogous reaction conditions, but using n-butanol instead of cyclohexanol, there was obtained butyl 1-ethyl-l,4-dihydro-6,7-methylenedioxy 4 oxo 3 quinolinecarboxylate, M.P. 131-133".
Analysis.Calcd. for C1I1H19NO5 (percent): C, 64.35; H, 6.04; N, 4.41. Found (percent): C, 64.23; H, 5.94; N, 4.23.
EXAMPLE 6 Following the procedure of Example 2 and employing analogous reaction conditions, but using t-amyl alcohol instead of cyclohexanol, there was obtained tert-amyl 1- ethyl-1,4-dhydro 6,7 methylenedioxy-4-oxo-3-quinolinecarboxylate, M.P. 172-173 AnaIysis.Calcd. for C H NO (percent): C, 65.24; H, 6.39; N, 4.23. Found (percent): C, 65.16; H, 6.36; N, 4.46.
EXAMPLE 7 Following the procedure of Example 2 and employing analogous reaction conditions, but using n-hexyl alcohol instead of cyclohexanol, there was obtained hexyl l-ethyl- 1,4-dihydro-6,7-methylenedioxy 4 oxo 3 quinolinecarboxylate, M.P. 92.
Analysis.Calcd. for C H NO (percent): C, 66.07; H, 6.71; N, 4.06. Found (percent): C, 65.90; H, 6.81; N, 4.19.
EXAMPLE 8 Following the procedure of Example 2 and employing analogous reaction conditions, but using n-decyl alcohol instead of cyclohexanol, there was obtained decyl l-ethyl- 1,4-dihydro-6,7-methylenedioxy 4 oxo 3 quinolinecarboxylate, M.P. 99-101".
Analysis.-Calcd. for C H NO (percent): C, 68.80; H, 7.78; N, 3.49. Found (percent): C, 69.07; H, 7.89; N, 3.70.
EXAMPLE 9 Following the procedure of Example 2 and employing analogous reaction conditions, but using diethylaminoethanol, instead of cyclohexanol, there was obtained 2- (diethylarnino)ethyl 1 ethyl-1,4-dihydro-6,7-methylenedioxy-4-oxo-3-quinolinecarboxylate, M.P. 108-109".
Analysis.Calcd. for C H N O (percent): C, 63.32; H, 6.71; N, 7.77. Found (percent): C, 63.52; H, 6.75; N, 7.48.
EXAMPLE 10 The acid chloride obtained by treatment of 1,4-dihydro- 1 methyl-6,7-methylenedioxy 4 oxo-3-quinolinecarboxylic acid with thionyl chloride as in Method A, Example 1, was treated, without isolation, with ethanol to yield ethyl 1,4-dihydro-1-methyl 6,7 methylenedioxy-4- oxo-3-quinolinecarboxylate, M.P. 202-203.
Analysis.Calcd. for C H NO (percent): C, 61.09; H, 4.76; N, 5.09. Found (percent): C, 61.26; H, 4.99; N, 5.08. I
EXAMPLE 11 The acid chloride obtained by treatment of 1,4-dihydro- 6,7 methylenedioxy-4-oxo l propyl 3 quinoline carboxylic acid with thionyl chloride, as in Method A, Example 1, was treated, without isolation, with ethanol to yield ethyl 1,4-dihydro 6,7 methylenedioxy 4 oxo-lpropyl-3-quinolinecarboxylate, M.P. 147l49.
Analysis.-Calcd. for C H NO (percent): C, 63.36; H, 5.65; N, 4.26. Found (percent): C, 63.34; H, 5.80; N, 4.44.
EXAMPLE 12 The acid chloride obtained by treatment of 1-butyl-1,4- dihydro-6,7-methy1enedioxy 4 oxo 3 quinoline carboxylic acid with thionyl chloride, as in Method A, Example 1, was treated, without isolation, with ethanol to yield ethyl 1-butyl-l,4-dihydro 6,7 methylenedioxy-4- oxo-3-quinoline carboxylate, M.P. 117-119".
Analysis.-Calcd. for C H NO (percent): C, 64.35; H, .6.0 4;;N,...4.41. Found (percent): C, 64.51; H, 6.23; N,
METHOD B.-EXAMPLE 1 V N-(Z-diethylaminoethyl) -1-ethyl-1,4-dihydro-4-oxo- 6,7-methylenedioxy-quinoline-3-carboxamide A mixture of 8.4 g. (0.03 mole) of 1-ethyl1,4-dihydro 4-oxo-6,7-methylenedioxy quinoline-3-carbonyl chloride, 4.6 g. (0.04 mole) of N,N-diethyl ethylenediamine and 150 ml. of benzene was refluxed for 8 hrs. The volatiles were removed under aspirator vacuum and the residue was triturated with 5% NaOH solution and recrystallized from aqueous isopropyl alcohol yielding 10.2 g. (94%), M.P. 192-195 of N- (2-diethylaminoethyl)-1- ethyl-1,4-dihydro-6,7-methylenedioxy 4 oxo 3 quinoline carboxamide, M.P. 19920l.
Analysis.-Calcd. for C H N O (percent): C, 63.49; H, 7.01; N, 11.69. Found (percent): C, 63.57; H, 7.05;
EXAMPLE 2 Following the procedure of Method C, Example 1, and using m-anisidine there was obtained 1-ethyl-1,4-dihydro-N (m-methoxyphenyl)-6,7-methylenedioxy-4-oxo- 3-quinoline carboxamide, M.P. 240-241.
Analysis.-Calcd. for C H N O (percent): C, 65.56; H, 4.95; N, 7.65. Found (percent): C, 65.50; H, 5.02;
METHOD C l-ethyl-1,4-dihydro-4-oxo-6,7-methylenedioxyquinoline- 3-hydroxamic acid 'Hydroxylamine hydrochloride (2.1 g., 0.03 mole) was added to a mixture of 4.2 g. (0.015 mole) of 1-ethyl-1,4- dihydro-4-oxo-6,7-methylenedioxyquino1ine 3 carbonyl chloride in 25 ml. of pyridine. After stirring for 2 hr., the mixture was heated for 3 hr. on a steam bath. The pyridine was removed under aspirator vacuum and the residue was recrystallized from 90% aqueous ethanol to yield 4.0 g. of light yellow crystals (96%) of 1-ethy1-1,4-
dihydro-6,7-methylenedioxy-4-oxo-3-quinoline hydroxamic acid, M.P. 265-268". The analytical sample from 95% ethanol had M.P. 269-270.
Analysis.-Calcd. for O l-1 N 0 (percent): C, 56.52; H, 4.38; N, 10.14. Found (percent): C, 56.77; H, 4.47; N, 10.10.
METHOD D ethyl l-ethyl-1,4-dihydro-4-oxo-6,7-methy1enedioxyquinoline-3-yl) carbonyl] carbamates A mixture of 8.4g. (0.03 mole) of 1-ethyl-1,4-dihydroingredient an anti-bacterially eifective amount of a com pound of the formula:
0 0 II 0 CH J wherein R is lower alkyl, hydroxy-lower alkyl, carboxylower alkyl, lower alkenyl, or cycloalkyl, in which cycloalkyl contains from 3 to 8 carbon atoms; R is NHOH, NHCOO'R in which R is lower alkyl in an inert pharmaceutical carrier.
2. A method for treating gram negative bacterial infections in a mammal which comprises administration to said mammal an eifective anti-bacterial amount of a composition according to claim 1.
3. A method according to claim 1 wherein said composition contains as active ingredient the compound having the following structural formula:
at a dose of about 25 mg. to 1500 mg. several times daily.
4. A method according to claim 3 wherein the composition of claim 1 is administered at a dose of about 250 mg. several times daily.
References Cited UNITED STATES PATENTS 2,614,121 10/1952 Price et al. 260-287 3,172,811 3/1965 Kaminsky et al. 260-287 3,290,315 12/1966 Watson 260-287 3,397,208 8/1968 Berman 260-287 JEROME D. GOLDBERG, Primary Examiner
US47893A 1970-06-19 1970-06-19 1,4-dihydro - 1 - substituted-6,7-methylenedioxy-4-oxo -3-quinoline carboxylic acid antibacterial agents Expired - Lifetime US3591697A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4789370A 1970-06-19 1970-06-19

Publications (1)

Publication Number Publication Date
US3591697A true US3591697A (en) 1971-07-06

Family

ID=21951598

Family Applications (1)

Application Number Title Priority Date Filing Date
US47893A Expired - Lifetime US3591697A (en) 1970-06-19 1970-06-19 1,4-dihydro - 1 - substituted-6,7-methylenedioxy-4-oxo -3-quinoline carboxylic acid antibacterial agents

Country Status (1)

Country Link
US (1) US3591697A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036962A (en) * 1974-08-12 1977-07-19 E. I. Du Pont De Nemours And Co. 6,7-Methylenedioxy-1-(2,2,2-trifluoroethyl)-4(1H)-quinolone-3-carboxylic acid and its salts and esters
US4284777A (en) * 1978-12-26 1981-08-18 E. I. Du Pont De Nemours And Company Antibacterials: 1-difluoromethyl-6,7-methylenedioxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid and its esters
US4379929A (en) * 1981-03-19 1983-04-12 Eli Lilly And Company 4(1H)-Oxocinnoline-3-carboxylic acid derivatives
WO2011146591A1 (en) * 2010-05-19 2011-11-24 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036962A (en) * 1974-08-12 1977-07-19 E. I. Du Pont De Nemours And Co. 6,7-Methylenedioxy-1-(2,2,2-trifluoroethyl)-4(1H)-quinolone-3-carboxylic acid and its salts and esters
US4284777A (en) * 1978-12-26 1981-08-18 E. I. Du Pont De Nemours And Company Antibacterials: 1-difluoromethyl-6,7-methylenedioxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid and its esters
US4379929A (en) * 1981-03-19 1983-04-12 Eli Lilly And Company 4(1H)-Oxocinnoline-3-carboxylic acid derivatives
WO2011146591A1 (en) * 2010-05-19 2011-11-24 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US8513421B2 (en) 2010-05-19 2013-08-20 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof

Similar Documents

Publication Publication Date Title
US3524858A (en) 1,4 - dihydro-1-substituted alkyl-6,7-methylenedioxy - 4 - oxoquinoline-3-carboxylic acid
EP1107968B1 (en) Dihydro-[1,2,3]triazolo-[4,5-d]pyrimidin-7-one
DE69524114T2 (en) NAPHTHYRIDINONDERIVATE
SU1122228A3 (en) Method of obtaining bis-esters of methadiol with penecillin and 1,1-dioxide of penicillanic acid
EP1339716B1 (en) lactam-substituted pyrazolopyridine derivatives
DE60008545T2 (en) ANTIBACTERIAL HETEROBICYCLIC SUBSTITUTED PHENYLOXAZOLIDINONE
DE60305446T4 (en) DESAZAPURINE AND ITS USE
DE69434380T2 (en) Pyridazino-quinoline compounds
US4956179A (en) Antibacterial combination of penicillin and cephalosporin
DE3702393A1 (en) 8-CYANO-1-CYCLOPROPYL-1,4-DIHYDRO-4-OXO- 3-CHINOLINE CARBONIC ACIDS, METHOD FOR THEIR PRODUCTION AND ANTIBACTERIAL AGENTS CONTAINING THEM
NO176356C (en) Analogous Process for the Preparation of New Therapeutically Active Pyrazolopyridine Compounds
EP0391132A1 (en) 5-Alkylquinolinone carboxylic acids
IE782070L (en) Azabicyclo (3.2.0) hept-2-ene carboxylic acid derivatives
US3506667A (en) Furo quinoline carboxylates
CH639665A5 (en) METHOD FOR PRODUCING AMINO DERIVATIVES OF CLAVULANINIC ACID.
US3591697A (en) 1,4-dihydro - 1 - substituted-6,7-methylenedioxy-4-oxo -3-quinoline carboxylic acid antibacterial agents
AU752263B2 (en) G-CSF mimetics
EP0429304A2 (en) Pyridone-carboxylic acid derivatives and their use as veterinary medicines
DE3876712T2 (en) ANTIANAEROBIC NAPHTHYRIDINE COMPOUNDS.
US3755588A (en) Penicillanic acid in dosage unit form
EP0607163B1 (en) NEUROLEPTIC 2-SUBSTITUTED PERHYDRO-1-H-PYRIDO[1,2-a]PYRAZINES
US3714206A (en) Benzo-2,3,1-diazaborines
US3681351A (en) CERTAIN 5,6,7,8-TETRAHYDRO-5,8-ETHANO-PYRIDINO{8 2,3-b{9 -THIENO{8 5,4-d{9 PYRIMIDINES
US4698350A (en) 1-ethyl-6-fluoro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl)-4-oxo-3-quinolinecarboxylic acid and antibacterial use thereof
DE69515498T2 (en) NAPHTHYRIDINE DERIVATIVES